Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
To describe 2 patients with relapsing-remitting multiple sclerosis (RRMS) receiving long-term treatment with the monoclonal antibody rituximab. The clinical and paraclinical efficacy of rituximab was demonstrated recently in a phase 2 clinical trial in patients with RRMS. Case series. Tertiary care university medical center. Two young patients with highly active RRMS in whom standard therapy had failed before receiving rituximab for up to 48 months. Relapse rate, clinical disability, and results of magnetic resonance imaging. Both patients tolerated rituximab treatment well and have been clinically stable throughout the study period. Long-term therapy with rituximab appears safe and effective in some patients with RRMS. Our observation should be confirmed in controlled long-term trials.